Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD

American Journal of Nephrology

Volumn 33, Issue 5, 2011, Pages 469-476

  Pergola, Pablo E ^a   Krauth, Melissa ^b   Huff, J Warren ^b   Ferguson, Deborah A ^b   Ruiz, Stacey ^b   Meyer, Colin J ^b   Warnock, David G ^c  

^a Renal Associates   (United States)

^b Reata Pharmaceuticals Inc   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Antioxidant inflammation modulator; Bardoxolone; Chronic kidney disease; Estimated glomerular filtration rate; Inflammation; Nrf2; Oxidative stress; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BARDOXOLONE METHYL; BILIRUBIN; CREATININE; NITROGEN; UREA;

ADULT; AGED; ALBUMINURIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD VESSEL INJURY; CHILL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; ENDOTHELIUM CELL; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGEUSIA; HYPOGLYCEMIA; KIDNEY FUNCTION; LIMB PAIN; LIVER FUNCTION TEST; MALE; MULTICENTER STUDY; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TIME; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION;

ADULT; AGED; ANTIOXIDANTS; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OLEANOLIC ACID; OXIDATIVE STRESS; PLACEBOS; TIME FACTORS;

EID: 79954582442     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000327599     Document Type: Article

References (35)

1. Cachofeiro V, Goicochea M, de Vinuesa SG, et al: Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008;111: S4-S9.
2. Eustace JA, Astor B, Muntner PM, et al: Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004;65:1031-1040. (Pubitemid 38251079)
3. Fried L, Solomon C, Shlipak M, et al: Inf lammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004;15:3184-3191. (Pubitemid 39578851)
4. Keller C, Katz R, Cushman M, et al: Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008;9:9.
5. Menon V, Greene T, Wang X, et al: C-reactive protein and albumin as predictors of allcause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005;68:766-772. (Pubitemid 43323132)
6. Muntner P, He J, Astor BC, et al: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-538. (Pubitemid 41725151)
7. Shlipak MG, Fried LF, Crump C, et al: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92. (Pubitemid 36070938)
8. Stuveling EM, Hillege HL, Bakker SJ, et al: C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003;63:654-661. (Pubitemid 36126812)
9. Tonelli M, Sacks F, Pfeffer M, et al: Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005;68:237-245. (Pubitemid 43181381)
10. Sanz AB, Sanchez-Nino MD, Ramos AM, et al: NF-κB in renal inflammation. J Am Soc Nephrol 2010;21:1254-1262.
11. Dinkova-Kostova AT, Liby KT, Stephenson KK, et al: Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005;102:4584-4589. (Pubitemid 40397155)
12. Honda T, Rounds BV, Gribble GW, et al: Design and synthesis of 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8:2711-2714. (Pubitemid 28496657)
13. Honda T, Honda Y, Favaloro FG Jr, et al: A novel dicyanotriterpenoid, 2-cyano-3, 12-dioxooleana-1, 9 (11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 2002;12:1027-1030. (Pubitemid 34242794)
14. Jin W, Zhu L, Guan Q, et al: Influence of Nrf2 genotype on pulmonary NF-κB activity and inflammatory response after traumatic brain injury. Ann Clin Lab Sci 2008;38:221-227.
15. Li W, Khor TO, Xu C, et al: Activation of Nrf2-antioxidant signaling attenuates NF-κB-inflammatory response and elicits apoptosis. Biochem Pharmacol 2008;76:1485-1489.
16. Thimmulappa RK, Lee H, Rangasamy T, et al: Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006;116:984-995.
17. Yan W, Wang HD, Zhu L, et al: Traumatic brain injury induces the activation of the Nrf2-ARE pathway in the lung in rats. Brain Inj 2008;22:802-810.
18. Kim HJ, Vaziri ND: Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010;298: F662-F671.
19. Hirayama A, Yoh K, Nagase S, et al: EPR imaging of reducing activity in Nrf2 transcriptional factor-deficient mice. Free Radic Biol Med 2003;34:1236-1242. (Pubitemid 36513966)
20. Li J, Stein TD, Johnson JA: Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice. Physiol Genomics 2004;18:261-272. (Pubitemid 39319509)
21. Yoh K, Itoh K, Enomoto A, et al: Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001;60:1343-1353. (Pubitemid 32960028)
22. Ma Q, Battelli L, Hubbs AF. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol 2006;168:1960-1974.
23. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
24. Levey AS, Coresh J, Greene T, et al: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254. (Pubitemid 46768608)
25. Aleksunes LM, Reisman SA, Yeager RL, et al: Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice. J Pharmacol Exp Ther 2010;333:140-151.
26. Cai D, Yuan M, Frantz DF, et al: Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 2005;11:183-190. (Pubitemid 40321354)
27. Saha PK, Reddy VT, Konopleva M, et al: The triterpenoid CDDO-Me has potent antidiabetic effects in diet-induced diabetic mice and Leprdb/db mice. J Biol Chem 2010.
28. Osburn WO, Yates MS, Dolan PD, et al: Genetic or pharmacologic amplification of Nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol Sci 2008;104:218-227. (Pubitemid 351859044)
29. Zhang YK, Yeager RL, Tanaka Y, et al: Enha nced ex pression of Nrf2 in m ice at tenuates the fatty liver produced by a methionineand choline-deficient diet. Toxicol Appl Pharmacol 2010;245:326-334.
30. Malhotra D, Portales-Casamar E, Singh A, et al: Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 2010;38:5718-5734.
31. Landray MJ, Wheeler DC, Lip GY, et al: Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the Chronic Renal Impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004;43:244-253. (Pubitemid 38146322)
32. Woywodt A, Kirsch T, Haubitz M: Circulating endothelial cells in renal disease: markers and mediators of vascular damage. Nephrol Dial Transplant 2008;23:7-10. (Pubitemid 351767418)
33. Yilmaz MI, Saglam M, Caglar K, et al: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006;47:42-50. (Pubitemid 41828265)
34. Devarajan P: NGAL in acute kidney injury: from serendipity to utility. Am J Kidney Dis 2008;52:395-399.
35. Bolignano D, Donato V, Coppolino G, et al: Neutrophil gelatinase-associated lipocalin as a marker of kidney damage. Am J Kidney Dis 2008;52:595-605.